Figure 1
Figure 1. Prognostic value of CDKN2A (p16) and TP53 deletions on OS in pooled treatment arms or in the experimental treatment arm (R-CHOP/R-DHAP). (A) OS according to the presence or absence of CDKN2A (p16) deletion in pooled treatment arms. (B) OS according to the presence or absence of CDKN2A (p16) deletion in the experimental treatment arm. (C) OS according to the presence or absence of TP53 deletion in pooled treatment arms. (D) OS according to the presence or absence of TP53 deletion in the experimental treatment arm. (E) OS according to the presence or absence of CDKN2A (p16) and TP53 deletions in pooled treatment arms. (F) OS according to the presence or absence of CDKN2A (p16) and TP53 deletions in the experimental treatment arm.

Prognostic value of CDKN2A (p16) and TP53 deletions on OS in pooled treatment arms or in the experimental treatment arm (R-CHOP/R-DHAP). (A) OS according to the presence or absence of CDKN2A (p16) deletion in pooled treatment arms. (B) OS according to the presence or absence of CDKN2A (p16) deletion in the experimental treatment arm. (C) OS according to the presence or absence of TP53 deletion in pooled treatment arms. (D) OS according to the presence or absence of TP53 deletion in the experimental treatment arm. (E) OS according to the presence or absence of CDKN2A (p16) and TP53 deletions in pooled treatment arms. (F) OS according to the presence or absence of CDKN2A (p16) and TP53 deletions in the experimental treatment arm.

Close Modal

or Create an Account

Close Modal
Close Modal